AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 41 min read$EDIT

Parison Amy sold $1K of EDIT

Parison Amy (SVP, Chief Financial Officer) sold 453 shares of Editas Medicine, Inc. (EDIT) at $3.04 on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Parison Amy
Published Sep 4, 2026, 8:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 8:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$EDIT
Neutral
high confidence
Mentioned
$EDIT
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EDITNeutralLow
01

Why it matters

The transaction is a routine insider sale with minimal market impact.

02

Market read

Low relevance; typical insider filing with negligible trading implications.

03

What to watch

Potential upcoming clinical data releases could change relevance of insider activity.

Relevance 2/10Novelty 4/10Timing: filed Sep 4 2026 after market close

Background

Editas Medicine is a CRISPR gene‑editing biotech; CFO disclosed a routine 10b5‑1 sale.

Company-level read

Ticker impact

$EDITNeutralHigh confidence
Context

Form 4 filing shows CFO Amy Parison sold 453 shares of Editas Medicine for $1,376 via a 10b5‑1 plan.

Expected impact

No significant impact expected.

Evidence & confidence

Sale size is trivial relative to float and disclosed via pre‑arranged plan.

Market effects

Sector

None; biotech sector unchanged.

Regional

None; US market only.

Global

None

Counterpoint

What could challenge this read

Even small insider sales can signal concerns; monitor future filings.

Key entities

  • company
    Editas Medicine, Inc.

    Biotech firm developing gene‑editing therapies.

  • person
    Parison Amy

    Chief Financial Officer of Editas Medicine.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

EDIT insider trading history →

Related articles

SEP 9
$EDITLowAI 8/10

Editas Medicine Eyes First Human Trial for CRISPR Cholesterol Therapy EDIT-401

Editas Medicine (NASDAQ:EDIT) plans to start a Phase 1 trial for its CRISPR-based cholesterol therapy, EDIT-401, in Australia this year. The trial aims to treat patients with heterozygous familial hypercholesterolemia. Preclinical data suggests a 15% allele edit could significantly lower cholesterol. The company has $212 million in cash and expects its runway to extend into mid-2028.

finance.yahoo.com2 min
AUG 5
$EDITMed

Editas Medicine, Inc. (EDIT): Results of Operations and Financial Condition

Editas Medicine, Inc. (EDIT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT-401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoprotei

SEC EDGAR 8-K4 min
MAY 28
$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

rttnews.com6 min
MAY 26
$EDITHighAI 9/10

Editas Presents Positive Preclinical Data For EDIT-401 In Treating Hyperlipidemia; Stock Down

Editas Medicine reported preclinical results for EDIT-401, an in vivo gene-editing system targeting the LDLR gene to lower LDL-C. In non-human primates, it showed about a 90% mean reduction in LDL-C and roughly 90% reductions in Lp(a) and ApoB, with correlated biomarker changes. GLP toxicology is ongoing with interim tolerability and no liver histopathology. The company plans an HeFH patient trial later this year and an IND filing after a successful FDA pre-IND meeting; shares fell on the news.

rttnews.com4 min